S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
S&P 500   4,974.66 (+0.15%)
DOW   38,006.49 (+0.05%)
QQQ   414.47 (-0.04%)
AAPL   165.18 (+0.11%)
MSFT   396.38 (-0.69%)
META   474.18 (-1.43%)
GOOGL   154.26 (+0.11%)
AMZN   174.68 (+0.03%)
TSLA   140.51 (-4.45%)
NVDA   773.81 (+1.55%)
AMD   146.35 (-0.20%)
NIO   3.83 (+0.79%)
BABA   70.00 (+1.35%)
T   16.37 (-0.85%)
F   12.59 (+3.71%)
MU   106.83 (+0.06%)
GE   149.43 (+0.93%)
CGC   7.66 (-3.40%)
DIS   111.97 (-0.57%)
AMC   3.31 (+4.75%)
PFE   26.31 (+1.19%)
PYPL   62.54 (+0.37%)
XOM   120.36 (+0.40%)
NASDAQ:CYRX

Cryoport (CYRX) Stock Price, News & Analysis

$16.07
-0.06 (-0.37%)
(As of 11:05 AM ET)
Today's Range
$15.91
$16.17
50-Day Range
$14.36
$18.83
52-Week Range
$9.00
$24.17
Volume
36,217 shs
Average Volume
444,910 shs
Market Capitalization
$790.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.63

Cryoport MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
15.5% Upside
$18.63 Price Target
Short Interest
Bearish
8.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.15 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.31) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.72 out of 5 stars

Transportation Sector

104th out of 112 stocks

Pharmaceutical Preparations Industry

390th out of 423 stocks

CYRX stock logo

About Cryoport Stock (NASDAQ:CYRX)

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

CYRX Stock Price History

CYRX Stock News Headlines

CryoPort Inc
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Assessing CryoPort: Insights From 5 Financial Analysts
Analyst Ratings For CryoPort
Cryoport Tanks On Chilling Results And Bad Decisions
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cryoport, Inc. (CYRX)
Recap: CryoPort Q4 Earnings
CryoPort earnings: here's what Wall Street expects
CryoPort Inc CYRX
Matson, Inc. (MATX)
MATX Jun 2024 80.000 put
MATX Mar 2024 100.000 call
Should You Buy CryoPort, Inc. (CYRX) After Golden Cross?
See More Headlines
Receive CYRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryoport and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYRX
Employees
1,170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.63
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+15.5%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-99,590,000.00
Pretax Margin
-42.59%

Debt

Sales & Book Value

Annual Sales
$233.26 million
Cash Flow
$0.39 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
44,198,000
Market Cap
$792.95 million
Optionable
Optionable
Beta
1.60
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

CYRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cryoport stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CYRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYRX, but not buy additional shares or sell existing shares.
View CYRX analyst ratings
or view top-rated stocks.

What is Cryoport's stock price target for 2024?

7 Wall Street analysts have issued 12-month price objectives for Cryoport's stock. Their CYRX share price targets range from $10.00 to $28.00. On average, they anticipate the company's stock price to reach $18.63 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for CYRX
or view top-rated stocks among Wall Street analysts.

How have CYRX shares performed in 2024?

Cryoport's stock was trading at $15.49 at the beginning of 2024. Since then, CYRX stock has increased by 4.1% and is now trading at $16.13.
View the best growth stocks for 2024 here
.

When is Cryoport's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYRX earnings forecast
.

How were Cryoport's earnings last quarter?

Cryoport, Inc. (NASDAQ:CYRX) issued its earnings results on Tuesday, March, 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.19. The company earned $57.26 million during the quarter, compared to the consensus estimate of $58.27 million. Cryoport had a negative net margin of 42.69% and a negative trailing twelve-month return on equity of 11.86%.

What ETF holds Cryoport's stock?

Inspire Small/Mid Cap ETF holds 20,223 shares of CYRX stock, representing 0.21% of its portfolio.

What guidance has Cryoport issued on next quarter's earnings?

Cryoport updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $242.0 million-$252.0 million, compared to the consensus revenue estimate of $253.2 million.

What other stocks do shareholders of Cryoport own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Block (SQ).

Who are Cryoport's major shareholders?

Cryoport's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.33%). Insiders that own company stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Ramkumar Mandalam, Richard J Berman, Robert J Hariri and Robert Stefanovich.
View institutional ownership trends
.

How do I buy shares of Cryoport?

Shares of CYRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYRX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners